DK3897646T3 - Macitentan til behandling af pulmonal arteriel hypertension - Google Patents

Macitentan til behandling af pulmonal arteriel hypertension Download PDF

Info

Publication number
DK3897646T3
DK3897646T3 DK19832954.2T DK19832954T DK3897646T3 DK 3897646 T3 DK3897646 T3 DK 3897646T3 DK 19832954 T DK19832954 T DK 19832954T DK 3897646 T3 DK3897646 T3 DK 3897646T3
Authority
DK
Denmark
Prior art keywords
macitentan
treatment
arterial hypertension
pulmonary arterial
pulmonary
Prior art date
Application number
DK19832954.2T
Other languages
English (en)
Inventor
Dénes Csonka
Wassim Fares
Hans Hoogkamer
Koen Torfs
Original Assignee
Actelion Pharmaceuticals Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=69147670&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3897646(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Actelion Pharmaceuticals Ltd filed Critical Actelion Pharmaceuticals Ltd
Application granted granted Critical
Publication of DK3897646T3 publication Critical patent/DK3897646T3/da

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/12Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DK19832954.2T 2018-12-21 2019-12-20 Macitentan til behandling af pulmonal arteriel hypertension DK3897646T3 (da)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
EP2018086724 2018-12-21
EP2019051830 2019-01-25
EP2019060151 2019-04-18
EP2019066494 2019-06-21
EP2019067186 2019-06-27
PCT/EP2019/086754 WO2020128017A1 (en) 2018-12-21 2019-12-20 Pharmaceutical composition for the treatment of pulmonary arterial hypertension

Publications (1)

Publication Number Publication Date
DK3897646T3 true DK3897646T3 (da) 2024-07-01

Family

ID=69147670

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19832954.2T DK3897646T3 (da) 2018-12-21 2019-12-20 Macitentan til behandling af pulmonal arteriel hypertension

Country Status (30)

Country Link
US (3) US11234980B2 (da)
EP (1) EP3897646B1 (da)
JP (2) JP2022512493A (da)
KR (1) KR20210109558A (da)
CN (1) CN113194953A (da)
AU (1) AU2019410727B2 (da)
BR (1) BR112021011999A2 (da)
CA (1) CA3123990A1 (da)
CL (1) CL2021001636A1 (da)
CO (1) CO2021007186A2 (da)
DK (1) DK3897646T3 (da)
ES (1) ES2983314T3 (da)
FI (1) FI3897646T3 (da)
HR (1) HRP20240875T1 (da)
HU (1) HUE067126T2 (da)
IL (1) IL284136A (da)
JO (1) JOP20210153B1 (da)
LT (1) LT3897646T (da)
MA (1) MA54522B1 (da)
MX (1) MX2021007455A (da)
PH (1) PH12021551371A1 (da)
PL (1) PL3897646T3 (da)
PT (1) PT3897646T (da)
RS (1) RS65689B1 (da)
SG (1) SG11202105098VA (da)
SI (1) SI3897646T1 (da)
SM (1) SMT202400274T1 (da)
TW (1) TWI841649B (da)
WO (1) WO2020128017A1 (da)
ZA (1) ZA202105111B (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102568472B1 (ko) 2017-02-27 2023-08-18 이도르시아 파마슈티컬스 리미티드 엔도텔린 관련 질환의 치료를 위한 4-피리미딘술파미드 유도체와 활성 성분의 조합물
US20210386944A1 (en) * 2018-10-12 2021-12-16 Sanotize Research Development Corp. Gas-evolving compositions and container and delivery systems
CA3123990A1 (en) 2018-12-21 2020-06-25 Actelion Pharmaceuticals Ltd Pharmaceutical composition for the treatment of pulmonary arterial hypertension
TW202042818A (zh) * 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
CN114728002A (zh) * 2019-11-29 2022-07-08 埃科特莱茵药品有限公司 治疗肺动脉高血压的方法
JP2024507905A (ja) * 2021-02-26 2024-02-21 アクテリオン ファーマシューティカルズ リミテッド 左心室補助装置を移植した患者の肺高血圧症を治療する方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU229403B1 (en) 2000-12-18 2013-12-30 Actelion Pharmaceuticals Ltd Novel sulfamides and their use as endothelin receptor antagonists
PT1928409E (pt) * 2005-09-12 2012-11-27 Actelion Pharmaceuticals Ltd Composição farmacêutica estável que compreende uma pirimidina-sulfamida
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
LT2315587T (lt) 2008-08-13 2018-01-10 Actelion Pharmaceuticals Ltd. Terapinės kompozicijos, turinčios macitentano
KR20260020212A (ko) 2016-11-10 2026-02-10 아레나 파마슈티칼스, 인크. 라리네팍 및 다른 제제의 조합에 의한 pah의 치료 방법
WO2018153925A1 (en) * 2017-02-22 2018-08-30 Amneal Pharmaceuticals Company Gmbh Stable pharmaceutical compositions comprising macitentan
KR102568472B1 (ko) 2017-02-27 2023-08-18 이도르시아 파마슈티컬스 리미티드 엔도텔린 관련 질환의 치료를 위한 4-피리미딘술파미드 유도체와 활성 성분의 조합물
CA3123990A1 (en) 2018-12-21 2020-06-25 Actelion Pharmaceuticals Ltd Pharmaceutical composition for the treatment of pulmonary arterial hypertension
TW202042818A (zh) 2019-01-25 2020-12-01 瑞士商艾克泰聯製藥有限公司 用於治療慢性血栓性肺高血壓之醫藥組成物
TW202103703A (zh) 2019-04-05 2021-02-01 瑞士商艾克泰聯製藥有限公司 用於治療門脈肺高血壓之方法
WO2021105164A1 (en) 2019-11-26 2021-06-03 Actelion Pharmaceuticals Ltd Pharmaceutical composition for the treatment of pulmonary vascular disease and/or cardiac dysfunction in fontan-palliated patients

Also Published As

Publication number Publication date
AU2019410727A1 (en) 2021-08-12
JOP20210153B1 (ar) 2024-12-22
JOP20210153A1 (ar) 2023-01-30
JP2022512493A (ja) 2022-02-04
FI3897646T3 (fi) 2024-06-26
KR20210109558A (ko) 2021-09-06
HUE067126T2 (hu) 2024-10-28
HRP20240875T1 (hr) 2024-10-11
SI3897646T1 (sl) 2024-08-30
SG11202105098VA (en) 2021-06-29
US11234980B2 (en) 2022-02-01
WO2020128017A1 (en) 2020-06-25
EP3897646B1 (en) 2024-05-22
CO2021007186A2 (es) 2021-06-10
PL3897646T3 (pl) 2024-07-22
PT3897646T (pt) 2024-07-08
MA54522B1 (fr) 2024-07-31
AU2019410727B2 (en) 2025-05-08
BR112021011999A2 (pt) 2021-09-08
JP2024105450A (ja) 2024-08-06
CN113194953A (zh) 2021-07-30
RS65689B1 (sr) 2024-07-31
PH12021551371A1 (en) 2021-11-29
ZA202105111B (en) 2023-03-29
LT3897646T (lt) 2024-07-10
MX2021007455A (es) 2021-08-05
US11464777B2 (en) 2022-10-11
MA54522A (fr) 2022-03-23
TWI841649B (zh) 2024-05-11
CL2021001636A1 (es) 2022-02-18
US20230020241A1 (en) 2023-01-19
EP3897646A1 (en) 2021-10-27
TW202034923A (zh) 2020-10-01
US20220096476A1 (en) 2022-03-31
US20210196715A1 (en) 2021-07-01
ES2983314T3 (es) 2024-10-22
CA3123990A1 (en) 2020-06-25
SMT202400274T1 (it) 2024-09-16
IL284136A (en) 2021-08-31

Similar Documents

Publication Publication Date Title
DK3897646T3 (da) Macitentan til behandling af pulmonal arteriel hypertension
DK3612215T3 (da) Sammensætninger til behandling af lungeinflammation
DK3743070T3 (da) Forbindelser til behandling af kinaseafhængige lidelser
DK3810581T3 (da) Krystalmodifikationer af odevixibat
DK3501542T3 (da) Esketamin til behandling af depression
DK3653617T3 (da) Fremgangsmåde til fremstillingen af (s)-nikotin fra myosmin
DK3740216T3 (da) Fremgangsmåder til vurdering af virale vektorers transduktionsstyrke
DK3512850T3 (da) Inhibitorer af menin-mll-interaktionen
DK3468966T3 (da) Inhibitorer af menin-mll-interaktionen
DK3325443T3 (da) Fremgangsmåde til fremstilling af pridopidin
DK4013412T3 (da) Ripretinib til behandling af gastrointestinale stromale tumorer
DK3833662T3 (da) Inhibitorer af protein-protein-interaktionen mellem KEAP-1-NRF2-
DK4101454T3 (da) Sammensætninger til behandling af hypertension
IL282311A (en) Use of reboxetine to treat narcolepsy
DK3807260T3 (da) Oprensning af nikotin
DK3946179T3 (da) Stomiposer
DK3833746T3 (da) Mini-gde til behandlingen af glykogenlagringssygdom iii
EP4002604A4 (en) Connector
DK3476838T3 (da) Fremgangsmåde til fremstilling af azoxystrobin
DK3373931T3 (da) Heterocykliske forbindelser til behandling af sygdom
DK3484475T3 (da) 1-methylnicotinamid til behandlingen af kardiovaskulær sygdom
DK3743064T3 (da) Behandling af proteinuri
DK3818078T3 (da) Fremgangsmåder til fremstilling af rekombinante proteiner
DK3856928T3 (da) Fremgangsmåde til karakterisering af modifikationer forårsaget af anvendelsen af designernukleaser
DK3801546T3 (da) Indolforbindelse til behandling af interstitiel cystitis